HRAS and head and neck squamous cell carcinoma: Core pathway components (HRAS, BRAF, MAPK1, RPS6KA1) are mutated in ~10.5% cases (54/512, TCGA-HNSCC cohort), while key scaffold proteins and negative regulators are mutated in ~4% and ~3% cases, respectively.